Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer

Micro-Abstract New intravesical therapies for non-muscle-invasive bladder cancer are strongly needed to decrease recurrence rates. In this study, the effective dose of TMX-101 was evaluated in 7 patients with low-grade disease. Despite preclinical effects of TMX-101 against urothelial carcinoma, no...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical genitourinary cancer Vol. 13; no. 3; pp. 204 - 209.e2
Main Authors:	Arends, Tom J.H, Lammers, Rianne J.M, Falke, Johannes, van der Heijden, Antoine G, Rustighini, Irene, Pozzi, Raffaella, Ravic, Miroslav, Eisenhardt, Andreas, Vergunst, Henk, Witjes, J. Alfred
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-06-2015
Subjects:	Administration, Intravesical Aminoquinolines - administration & dosage Aminoquinolines - adverse effects Aminoquinolines - pharmacokinetics Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Bladder cancer Bladder instillation Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - surgery Cystoscopy Dose-Response Relationship, Drug Female Hematology, Oncology and Palliative Medicine Humans Immunotherapy Interleukin 1 Receptor Antagonist Protein - urine Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Kidney Neoplasms - surgery Male Middle Aged Prospective Studies Toll-like receptor 7 Treatment Outcome Urology Treatment outcome Toll-like receptor 7 Bladder instillation Bladder cancer Immunotherapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Micro-Abstract New intravesical therapies for non-muscle-invasive bladder cancer are strongly needed to decrease recurrence rates. In this study, the effective dose of TMX-101 was evaluated in 7 patients with low-grade disease. Despite preclinical effects of TMX-101 against urothelial carcinoma, no effect was observed in these patients. New dosages and other bladder cancer subgroups should be tested to evaluate the potential effectiveness of TMX-101.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1558-7673 1938-0682
DOI:	10.1016/j.clgc.2014.12.010